Literature DB >> 27437932

Observed Patterns of Systemic Disease on PET/CT Scan in Patients with Presumed Ocular Tuberculosis: Findings and Hypotheses.

Salil Mehta1.   

Abstract

PURPOSE: To report the clinical, investigational and PET/CT scan findings of patients with presumed ocular tuberculosis and suggest a hypotheses for the pathogenesis.
METHODS: Retrospective case review. Included were 10 males and 17 females with an age range: 23-71 years.
RESULTS: Clinical findings include granulomatous or non-granulomatous anterior uveitis, intermediate uveitis, panuveitis, vasculitis, and multifocal serpiginous-like choroidopathy. A total of 13 PET/CT scans were normal and 14 showed systemic disease. The commonest finding was metabolically active lymphadenopathy and was seen in 14 patients. Mediastinal lymphadenitis was seen in 12 patients, 3 patients had abdominal/pelvic lymphadenopathy and 3 patients had additional cervical lymphadenopathy. Two patients had only cervical lymphadenitis. One patient had lung parenchymal disease and one had bone/joint disease. The commonest pathology was lymphadenitis.
CONCLUSIONS: Uveitis is part of an immune response to mycobacteria that manifests as lymphadenitis in the chest/abdomen and as a uveitis.

Entities:  

Mesh:

Year:  2016        PMID: 27437932     DOI: 10.1080/09273948.2016.1194436

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  3 in total

1.  Patterns of ocular inflammation in patients with miliary tuberculosis.

Authors:  Salil Mehta
Journal:  F1000Res       Date:  2017-04-03

Review 2.  BTS clinical statement for the diagnosis and management of ocular tuberculosis.

Authors:  Onn Min Kon; Nicholas Beare; David Connell; Erika Damato; Thomas Gorsuch; Guy Hagan; Felicity Perrin; Harry Petrushkin; Jessica Potter; Charanjit Sethi; Miles Stanford
Journal:  BMJ Open Respir Res       Date:  2022-03

Review 3.  Sarcoid Uveitis: An Intriguing Challenger.

Authors:  Pia Allegri; Sara Olivari; Federico Rissotto; Roberta Rissotto
Journal:  Medicina (Kaunas)       Date:  2022-07-04       Impact factor: 2.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.